Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 4Small Cell Lung Carcinoma 2Thymoma 1Stomach Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Radiotherapy 5Cisplatin 5pembrolizumab 4Cyclophosphamide 4Thymectomy 3Sunitinib 3130-nm albumin-bound paclitaxel 3selinexor 2Pemetrexed 2Methylprednisolone 2Etoposide 2Drug Therapy 2Doxorubicin 2Chemoradiotherapy 2Carboplatin 2zimberelimab 1vorolanib 1regorafenib 1lenvatinib 1epacadostat 1envafolimab 1bosutinib 1amrubicin 1Thoracic Surgery, Video-Assisted 1TP protocol 1Ramucirumab 1Radiotherapy, Adjuvant 1Radiosurgery 1Radiofrequency Ablation 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thymoma × vorolanib × Clear all
NCT03583086 2024-10-08

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Vanderbilt-Ingram Cancer Center

Phase 1/2 Completed
88 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡